Organisation/Company: Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino (NEUROFARBA), Università di Firenze
Research Field: Pharmacological sciences » Clinical pharmacology
Researcher Profile: Recognised Researcher (R2), Leading Researcher (R4), First Stage Researcher (R1), Established Researcher (R3)
Country: Italy
Application Deadline: 22 Jan 2025 - 23:59 (UTC)
Type of Contract: To be defined
Job Status: Not Applicable
Is the job funded through the EU Research Framework Programme? Not funded by a EU programme
Is the Job related to staff position within a Research Infrastructure? No
Offer Description
Several studies have demonstrated the central role of the brain HA system in cognition through genetic or pharmacological approaches. However, their inherent limitations restrict the understanding of the role of endogenous HA transmission in these processes. This study will employ chemogenetic technology to determine the role of endogenous HA on aversive memory consolidation and extinction. Anterograde and retrograde viral vectors carrying the inhibitory (hM4Di) or excitatory (hM3Dq) DREADDs will be injected in the TMN of HDC-Cre mice to specifically target HA neurons. After a recovery period and optimal viral expression, animals will receive systemic injections of the specific DREADDs activator clozapine-N-oxide, and their behavior will be assessed in the contextual fear conditioning paradigm.
Where to Apply
Website
Requirements
Eligibility criteria:
* Italy
Eligibility of fellows: country/ies of residence:
* OTHER
Eligibility of fellows: nationality/ies:
#J-18808-Ljbffr